EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study

Elizabeth M Gaughan, Miso Kim, Ignacio Mendez, Aparna D Rao, Maria Wei, Alexandra So, Xiaochen Zhong, Carola Berking, Ruixuan Jiang, Tae Min Kim, Stéphane Dalle, Caroline Robert und 27 weitere

Journal for ImmunoTherapy of Cancer · 2026

DOI: 10.1136/jitc-2025-014564 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal for ImmunoTherapy of Cancer, 2026. Verfasst von Elizabeth M Gaughan und 38 weiteren Autor:innen. Beteiligte Einrichtung: University of Virginia Cancer Center, Charlottesville, Virginia, USA. Hauptthemen laut MEDLINE: Melanoma, Immune Checkpoint Inhibitors, Programmed Cell Death 1 Receptor, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Anti-programmed cell death protein 1 (PD-1) immunotherapy has revolutionized the treatment of stage III and IV melanoma. Real-world data on its resistance is needed to facilitate the development of combinatorial approaches to overcome anti-PD-1 resistance.

Objectives

To characterize anti-PD-1 resistance and assess whether progressive disease assigned by clinicians is concordant with scan data assessed by independent central reviewers (ICR).

Methods

A retrospective chart review was conducted in adult patients with stage III/IV melanoma who initiated anti-PD-1 therapy from January 2018 until 12 months before the start of data collection at 22 sites across six countries. Primary resistance and late relapse in the adjuvant setting, and primary, secondary resistance, and late progression in the advanced setting were assigned using Society for Immunotherapy of Cancer definitions. Demographic and clinical characteristics by type of resistance were compared with appropriate univariate tests. Time to resistance (TTR) and overall survival were analyzed using Kaplan-Meier. To compare the concordance of progression assigned by clinicians and ICR, the positive predictive value (PPV) was calculated in a subset of patients.

Results

Of 981 eligible patients, 738 were included. In the adjuvant setting (n=240), 53 (22.1%) patients developed primary resistance and 60 (25.0%) experienced late relapse. In the advanced setting (n=498), 222 (44.6%), 50 (10.0%), and 64 (12.9%) patients developed primary, secondary resistance, and late progression. Type of resistance significantly differed by country, race, type of BRAF mutation, and PD-L1 expression in both settings; and by sex, disease stage and tumor thickness in the adjuvant setting only (p

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaImmune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorDrug Resistance, NeoplasmImmunotherapyHumansFemaleMaleRetrospective StudiesNeoplasm StagingMiddle AgedAgedAdult

Stichwörter der Autor:innen

AdjuvantImmune Checkpoint InhibitorImmunotherapyMelanoma

Substanzen

Immune Checkpoint InhibitorsProgrammed Cell Death 1 ReceptorPDCD1 protein, human

Autor:innen und Institutionen

  • University of Virginia Cancer Center, Charlottesville, Virginia, USA.
  • Seoul National University Hospital, Seoul, South Korea.
  • OXON Epidemiology, Madrid, Spain.
  • Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.
  • Melanoma Research Victoria, Melbourne, Victoria, Australia.
  • University of California San Francisco, San Francisco, California, USA.

Förderung

  • Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA

Zitieren

APA

Gaughan, E. M., Kim, M., Mendez, I., Rao, A. D., Wei, M., So, A., Zhong, X., Berking, C., Jiang, R., Kim, T. M., Dalle, S., Robert, C., Danson, S., Alam, S., Charles, J., Davies, T., Debus, D., Dzienis, M., Frazer, R., …, & Sullivan, R. J. (2026). Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study. Journal for ImmunoTherapy of Cancer. https://doi.org/10.1136/jitc-2025-014564

Vancouver

Gaughan EM, Kim M, Mendez I, Rao AD, Wei M, So A, et al. Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study. Journal for ImmunoTherapy of Cancer. 2026. doi:10.1136/jitc-2025-014564

BibTeX
@article{Gaughan2026,
  author = {Gaughan, Elizabeth M and Kim, Miso and Mendez, Ignacio and Rao, Aparna D and Wei, Maria and So, Alexandra and Zhong, Xiaochen and Berking, Carola and Jiang, Ruixuan and Kim, Tae Min and Dalle, Stéphane and Robert, Caroline and Danson, Sarah and Alam, Salma and Charles, Julie and Davies, Tessa and Debus, Dirk and Dzienis, Marcin and Frazer, Ricky and Gebhardt, Christoffer and Geidel, Glenn and Hassel, Jessica C and Hansen, Inga and Heppt, Markus Vincent and Hildebrandt, Lina and Isaacs, James M and Suh, Koung Jin and Keam, Bhumsuk and Kim, Yu Jung and Lesimple, Thierry and Saiag, Philippe and Delibes, Alicia and Barnett, Rosemarie and Krepler, Clemens and Gandhi, Kavita and Qizilbash, Nawab and Shui, Irene M and Tan, Xiang-Lin and Sullivan, Ryan J},
  title = {Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study},
  journal = {Journal for ImmunoTherapy of Cancer},
  year = {2026},
  doi = {10.1136/jitc-2025-014564}
}
Kostenlos starten →